Table 2.
Distribution of genetic polymorphism according to risk factors (any grade of neutropenia and neuropathy).
| Gene variants | Patients | p-value* | OR (95% CI)** | |
|---|---|---|---|---|
| Control cohort N = 41 (%) | Taxane users N = 35 (%) | |||
| ABCB1 Iso1145Iso | 0.50 | |||
| “CC” | 15 (36.6) | 13 (37.1) | 1 | |
| “CT” | 23 (56.1) | 18 (51.4) | 0.57 (0.20–1.66) | |
| “TT” | 3 (7.3) | 4 (11.5) | 1.67 (0.26–10.67) | |
| ABCB1 Ala893Ser | 0.40 | |||
| “GG” | 15 (36.6) | 19 (54.3) | 1 | |
| “GT/A” | 22 (53.7) | 14 (39.6) | 0.56 (0.21–1.47) | |
| “TT/AA” | 4 (9.8) | 2 (6.1) | 0.44 (0.07–2.76) | |
| CYP3A4*1B 5′UTR | 0.70 | |||
| “AA” | 29 (70.7) | 26 (74.3) | 1 | |
| “AG+GG” | 12 (29.3) | 9 (25.7) | 0.60 (0.20–1.83) | |
| CYP2C8*3 Lys399Arg | 0.19 | |||
| “TT” | 28 (75.7) | 25 (71.4) | 1 | |
| “CT” | 6 (16.2) | 10 (28.6) | 1.62 (0.49–5.35) | |
| “CC” | 3 (8.1) | 0 | n.d. | |
| CYP3A4*22 intron 6 | 0.30 | |||
| “CC” | 38 (92.7) | 30 (85.7) | 1 | |
| “CT” | 3 (7.3) | 5 (14.3) | 2.17 (0.48–9.79) | |
| GSTP1 Iso105Val | 0.70 | |||
| “AA” | 25 (70.0) | 22 (62.9) | 1 | |
| “AG” | 16 (30.0) | 13 (37.1) | 1.25 (0.44–3.60) | |
| SLCO1B1 Val174Ala | 0.60 | |||
| “TT” | 27 (65.8) | 27 (77.1) | 1 | |
| “CT” | 12 (29.3) | 8 (22.9) | 1.03 (0.35–3.06) | |
| “CC” | 2 (4.9) | 0 | n.d. | |
| ABCG2 Val12Met | 0.40 | |||
| “CC” | 35 (85.4) | 27 (77.1) | 1 | |
| “CT” | 4 (9.8) | 3 (8.6) | 1.0 (0.2–4.84) | |
| “TT” | 2 (4.8) | 5 (14.3) | 3.33 (0.6–18.5) | |
| ERCC2 Lys751Gln | 0.40 | |||
| “TT” | 22 (53.7) | 14 (40) | 1 | |
| “GT” | 14 (34.1) | 15 (42.9) | 1.76 (0.66–4.71) | |
| “GG” | 5 (12.2) | 6 (17.1) | 1.97 (0.51–7.68) | |
| XRCC3 Thr241Met | 0.03 | |||
| “AA” | 34 (82.9) | 23 (65.7) | 1 | |
| “AG” | 7 (17.1) | 7 (20.0) | 1.52 (0.5–4.91) | |
| “GG” | 0 | 5 (14.3) | n.d. | |
| “AG”+“GG” | 12 (34.3) | 2.61 (0.90–7.61) | ||
*
Chi-Square test;
**
Crude odds ratio logistic regression were adjusted for age and gender. In bold are significative results.
Distribution of genetic polymorphism according to neutropenia and neurotoxity with the distinction for grading among 35 Taxane users only, are provided in the Supplementary Table 2.